The potent insulin-sensitizing effects of peroxisome proliferator-activated receptor g (PPARg) agonists are well established. However, it is still a matter of intense debate as to which tissue(s) represent the most critical sites of action for PPARg agonists, and what the relevant target genes are that ultimately mediate the improvements in insulin sensitivity. The cell type with the highest levels of PPARg is the adipocyte, and as such the adipocyte is an excellent candidate cell to look for critical mediators of PPARg agonist action. Adiponectin, an adipocyte-specific secretory protein, is upregulated in response to PPARg agonist exposure, and its serum levels consequently increase significantly. Genetic, pharmacological and clinical studies have demonstrated potent insulin-sensitizing effects of adiponectin. Here, we summarize the evidence that implicates adiponectin as a critical mediator of PPARg-agonist-mediated improvements in insulin sensitivity, particularly in the context of PPARg-agonistmediated enhancements of hepatic insulin sensitivity.
Introduction
The prevalence of obesity and diabetes has dramatically increased over the past 15 years and is rapidly reaching epidemic proportions in developed countries. 1 A number of studies estimate the prevalence of obesity at nearly 20% and that of diabetes at around 8% in the US. These figures represent a 50% increase over the past decade. Diabetes is a chronic disease characterized by an improper regulation of carbohydrate and lipid metabolism by insulin, resulting in elevated fasting and postprandial serum glucose concentrations. If left untreated, chronic hyperglycemia leads to microvascular pathologies in the retina, in the renal glomerus and in peripheral nerves. Atherosclerotic macrovascular complications also arise, resulting in an elevated risk for myocardial infarction, stroke and limb amputations. Insulin resistance is the hallmark of early pathological defects in type 2 diabetes and also represents a characteristic feature of the metabolic syndrome (syndrome X) that includes other metabolic disorders such as dyslipidemia and hypertension. Several oral antidiabetic drugs are available that alleviate hyperglycemia. 2, 3 These oral antidiabetics act at a number of different levels. Compounds that increase insulin secretion include the sulfonylureas (potent insulin secretagogues) and the meglitinides (rapid-acting insulin secretagogues targeting a postprandial hyperglycemia) and act primarily by increasing insulin release from the pancreatic b cells. The biguanides, such as metformin, lower blood glucose concentration by reducing hepatic glucose output. aGlucosidase inhibitors are competitive inhibitors of the enteric enzyme responsible for the breakdown of polysaccharides into monosaccharides. This enzyme is required for proper absorption of dietary carbohydrates. All of the above therapeutic agents have relatively weak antidiabetic activity and several side effects. The thiazolidinediones (TZDs) or glitazones are a new class of antidiabetic drugs that act by ameliorating insulin resistance systemically, thereby resulting in thorough improvements in insulin-mediated repression of gluconeogenesis and stimulation of glucose uptake in skeletal muscle. 4 A major advantage of the TZD over other antidiabetic drugs is that improvement of insulin sensitivity following TZD treatment also results in improvements in b cell function. In addition, TZDs allow for the normalization of blood glucose without a concomitant risk of hypoglycemia (which is a concern with biguanides) and have potential benefits on the macrovascular complications of type 2 diabetes.
PPARc is the primary target transcription factor for TZDs
The first TZD, ciglitazone, was discovered in the 1980s by Kawamatsu and colleagues upon screening analogues of clofibric acid for antilipidemic effects. [5] [6] [7] They found that ciglitazone had both antilipidemic and antihyperglycemic effects. Lehman and colleagues were subsequently the first to identify peroxisome proliferator-activated receptor g (PPARg) as a molecular target for TZDs. 8 Binding affinities of TZDs for PPARg were also shown to correlate with the potency of their antidiabetic action, suggesting that the insulin-sensitizing effect of TZDs are mediated through activation of PPARg. 9 Identification of a dominant-negative mutation in the PPARg gene in two families with an inherited form of type 2 diabetes further underscores the importance of this transcription factor in insulin sensitivity. 10 The first clinically available TZD, troglitazone, has been associated with rare cases of idiosyncratic hepatotoxicity and was subsequently withdrawn from the European and US markets. Currently, two other TZDs are used for the treatment of type 2 diabetes in monotherapy or in combination with other antidiabetic drugs: rosiglitazone and pioglitazone. Despite the wide usage of these antidiabetic drugs, the precise molecular mechanisms underlying TZD action are not completely understood. The identification of PPARg target genes and the characterization of their physiological functions is the key to our understanding of the underlying mechanism of insulin sensitization of these drugs.
The PPARs are ligand-activated transcription factors. They comprise a subfamily of the nuclear hormone receptor superfamily that includes receptors for steroid, thyroid and retinoid hormones. They heterodimerize with the retinoid X receptor, bind to specific consensus DNA sequences (PPARresponsive elements or PPREs) and, upon agonist binding, induce the expression of target genes. This mechanism involves the recruitment of a multiprotein coactivator complex that acetylates histones and interacts with the basal transcription machinery of the target genes. Three isoforms, PPARa, g and d, encoded by separated genes, have been identified so far. PPARa is predominantly expressed in the liver, where it regulates the expression of genes involved in lipid oxidation. The fibrate class of antilipidemic drugs lowers triglycerides and raises high-density lipoproteins cholesterol, primarily through PPARa activation. PPARd is expressed in a broad range of tissues at comparable levels but its role is only now being elucidated. It is implicated in fatty acid-controlled differentiation of preadipocytes. Recent findings suggest that PPARd coordinates fatty acid oxidation and energy dissipation in peripheral tissues.
11 PPARg2, the isoform predominantly expressed in adipose tissue, is involved in terminal differentiation of adipocytes in white adipose tissue (WAT) and brown adipose tissue. 12 It is also a key regulator for the expression of numerous genes involved in lipid metabolism (lipoprotein lipase, fatty acid transporter protein, adipocyte fatty acid transporter protein, fatty acyl CoA synthase and malic enzyme), glucose metabolism (glucokinase and the GLUT4 glucose transporter) and energy balance (mitochondrial uncoupling proteins and leptin).
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PPARg is also implicated in the regulation of genes that affect insulin action negatively. TNFa is an inflammatory cytokine secreted by adipocytes. Elevated local production of TNFa has been associated with insulin resistance and decreased insulin signal transduction. PPARg agonists downregulate the expression of TNFa in adipose tissue and improve TNFainduced desensitization to insulin action. 14 PPARg is expressed in a number of cell types in different tissues. It is not clear which of the cell types that express PPARg represents the most essential site of TZD action. The high level of expression of PPARg in adipocytes makes the adipocyte an ideal candidate cell. In support of this idea is the observation that TZDs have no insulin sensitizing effect in A-ZIP/F1 mice, a model of insulin resistance that lacks WAT. Interestingly, the hypolipidemic effects of these drugs are unaffected in the same mouse model. 15 The role of PPARg in adipocyte differentiation and the ability of TZDs to stimulate adipocyte differentiation via PPARg are well documented. 4 Chronic TZD treatment results in weight gain, primarily due to an increase in fat mass. 16 The improvement in insulin sensitivity combined with an increase in fat mass seems paradoxical. Okuno and colleagues demonstrated that TZD treatment of obese Zucker rats triggers an increase in adipocyte differentiation, generating small, more insulin-responsive adipocytes and enhancing apoptosis of large ones. In the same study, a troglitazone treatment normalized the expression level of TNFa and caused a decrease in the expression level of leptin.
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The insulin-sensitizing effects of TZDs are achieved through improvements in insulin-mediated repression of gluconeogenesis at the level of the hepatocyte and ultimately result in a potentiation in insulin-stimulated postprandial glucose uptake by skeletal muscle. In light of the fact that expression levels are very low in muscle and in the liver, it is unclear whether PPARg in these cells represents a direct target for TZD action, or whether the antidiabetic effects observed in muscle and in the liver are secondary to TZD action in adipocytes through induction of an adipocyte hormonal factor. Using the Cre-Lox-P-mediated gene targeting, two recent reports described the generation of mice specifically lacking PPARg in muscle and showed that this deletion leads to secondary insulin resistance in the liver and adipose tissue. 18, 19 Treatment of this mouse model with troglitazone did not improve skeletal muscle insulin resistance but ameliorated hepatic and adipose insulin sensitivity, supporting the idea that muscle cells directly respond to PPARg agonist treatment, but that local PPARg in muscle is not an essential contributor to systemic antidiabetic effect of TZDs. Ablation of PPARg in mature adipocytes results in improvements of hepatic insulin sensitivity in response to TZD treatment, but did not lower serum triglycerides and free fatty acids. 20 PPARg in b cells is not required for the antidiabetic actions of TZDs. 21 Mice lacking PPARg in the More recently, two new factors exclusively secreted by adipocytes, resistin and adiponectin (also named Acrp30, AdipoQ and GBP28), have been identified and implicated as mediators of systemic insulin sensitivity. Interestingly, these two molecules exert opposite effects on hepatic insulin sensitivity. Elevated levels of resistin are associated with insulin resistance, 24 whereas adiponectin increases insulin sensitivity by enhancing insulin-mediated suppression of hepatic glucose production. 25 The latter protein was initially identified in a subtractive hybridization screen comparing 3T3-L1 adipocytes with undifferentiated adipocytes. 26 Adiponectin mRNA expression is dramatically induced during adipogenesis. The transcript encodes a hydrophilic protein of 247 amino acids, exclusively expressed in adipocytes. The protein was initially named adipocyte complement-related protein of 30 kDa (Acrp30), according to its closest homologue, complement factor C1q, and its size as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The secondary structure of Acrp30 comprises an N-terminal collagenous domain and a C-terminal globular domain. The C-terminal structure is similar to that of TNFa. 27 The basic building block of the protein is a homotrimer, formed initially through interactions between the globular domains and further stabilized by the collagenous triple helix. Through interactions within the collagenous domain, these trimers can associate into hexamers and higher-order structures composed of two to three hexamers. With a total concentration of 5-20 nM, adiponectin exists in the circulation in the two aforementioned discrete oligomeric structures: the hexamer or low molecular weight form (LMW form) and the higher-order structure or high molecular weight form (HMW form). 28 A characteristic sexual dimorphism is found in mice and humans, with higher levels of the total adiponectin found in females. 29 In terms of complex distribution, the majority of adiponectin in males is present in the LMW form (while the HMW circulates in subnanomolar concentrations), whereas females display a more balanced distribution of the two complexes. confirmed the association of obesity and type 2 diabetes with hypoadiponectinemia in Pima Indians and in HIV-positive patients. In ob/ob mice, adiponectin mRNA levels are downregulated as well. 34 Conversely, weight reduction in humans and mice 29, 35 leads to a significant increase in adiponectin plasma levels and a concomitant increase in insulin sensitivity. Moreover, the locus encoding the adiponectin gene has been identified as a susceptibility gene for insulin resistance and type 2 diabetes. Injection of recombinant full-length protein into mice has demonstrated profound effects on glucose metabolism in the liver, whereas only minimal effects were observed on muscle. 36 In particular, insulin-mediated repression of hepatic gluconeogenesis is significantly enhanced, both in vitro, using primary hepatocytes, and in vivo. AMPK activation seems to play an essential role in this process. 37 This is in contrast to results obtained with a smaller fragment of adiponectin, the so-called 'globular domain' (gAD) that comprises only the C-terminal globular fragment but lacks all N-terminal domains. gAD acts exclusively on muscle, where it stimulates AMPK activity as well. 38, 39 Since this fragment has not been visualized in vivo, and in light of several independent lines of evidence pointing towards an exclusive site of action in the liver in vivo, the gAd-induced changes in muscle hint at interesting pharmacological effects of this ligand, but lack a physiological correlate at this stage.
Adiponectin, a mediator of PPARc agonist action in the liver? levels displays remarkable parallels to prolonged exposure to TZDs, including a marked improvement in insulin sensitivity in the liver. 40 Given this observation and the fact that both TZDs and adiponectin affect hepatic insulin sensitivity in similar ways, several laboratories have raised the possibility that the TZD-mediated effects in the liver may be mediated through the upregulation and increased secretion of adiponectin from adipocytes. [41] [42] [43] [44] A common observation in all studies published to date is that the vast majority of patients or mice treated with TZD respond with an upregulation of serum adiponectin levels. We have demonstrated that a daily gavage of db/db mice or a chemically induced type 2 diabetes model (high-fat fed combined with low-dose streptozotocin treatment) with rosiglitazone for 11 days significantly decreased serum triglycerides and fasting glucose levels while leading to a dramatic three-to four-fold increase in serum adiponectin serum levels. Interestingly, the increase in serum adiponectin levels preceded the lowering of glucose levels slightly, consistent with a causal relationship between the two. 41 Improvement of systemic insulin sensitivity by other means, such as by direct activation of PPARa in the liver with fenofibrates, or by directly activating AMPK activity with metformin, failed to induce adiponectin levels, eliminating the possibility that mere metabolic improvement per se can induce adiponectin levels. Maeda et al investigated the effect of TZDs on adiponectin plasma levels in patients and rodents as well as in vitro using 3T3-L1 adipocytes. Treatment of mildly overweight subjects with glucose intolerance with either a placeboor 200 or 400 mg/day of troglitazone for 12 weeks resulted in a dose-dependent increase in plasma adiponectin with no change in BMI. In the same report, diabetic db/db mice displayed a similar elevated adiponectin plasma concentration in response to TZD treatment as well as an increase of adiponectin mRNA levels in adipose tissue. 42 The exact mechanism by which TZDs induce plasma adiponectin levels is poorly understood. However, Maeda et al demonstrated that TZD treatment induces the adiponectin promoter activity by five to 10-fold, suggesting that the induction of adiponectin expression is a consequence of a direct activation of the adiponectin promoter. This work was further confirmed and extended by Iwaki et al, 45 who revealed the existence of a PPRE in the human adiponectin gene. Finally, patients with dominant-negative PPARg mutations responsible for severe insulin resistance and type 2 diabetes have significantly decreased adiponectin levels, again implying that adiponectin is a molecular target of PPARg action. In these patients, treatment with rosiglitazone did not result in a significant activation of PPARg, nor was there any effect on adiponectin levels, confirming that PPARg activity is necessary for the transcriptional upregulation as well as the increased production and secretion of adiponectin from adipocytes. However, the fact that TZD treatment leads to an increase in adiponectin expression and secretion in the vast majority of patients, whereas only 50-70% of the treated patients show an actual improvement of insulin sensitivity, 46 raises serious issues with respect to a direct involvement of adiponectin in TZD action. This is further underlined by the observation that in patients who do respond, there is no strong correlation between fold-induction of adiponectin and quantitative aspects of improvements in insulin sensitivity. This discrepancy leads to the conclusion that the total adiponectin level is an insufficient parameter to explain the wide range of clinical responses to TZDs. Additionally, the correlations between insulin sensitivity and adiponectin levels in humans do not hold up equally well in many genetic mouse models of obesity and diabetes. db/db mice and lean heterozygote littermates have comparable levels of total adiponectin despite a marked difference in insulin sensitivity. 47 However, analysis of the relative distribution of the adiponectin complexes in these mice indicates a marked reduction in the percentage of the HMW form of the protein in db/db mice compared to lean db/ þ animals. 47 The same study also demonstrates that human insulin-resistant subjects have a significantly decreased HMW/total adiponectin ratio compared to lean controls, even when adjusted to the same total adiponectin levels. These observations give rise to the hypothesis that the relative levels of the HMW form, rather than the total amount of adiponectin, may be a more accurate indicator of insulin sensitivity. In fact, intravenous injection of purified HMW and LMW complexes showed that only the HMW form was able to decrease serum glucose, suggesting that the HMW form is the biologically active form of the protein in the liver. Exposure to TZDs leads to an induction of the HMW form in serum, both in mice and humans. Interestingly, patients who fail to increase the total circulating levels of adiponectin, yet shift the relative proportion of complexes towards a higher contribution of the HMW, improve insulin sensitivity. Others who increase total levels, yet have an unchanged proportion of HMW complexes, fail to respond with respect to insulin sensitivity. A novel index was defined, the adiponectin sensitivity index (S A ), which is defined as the relative level of HMW per total adiponectin (Figure 1) . 47 Monitoring the TZD-induced changes in S A (ie DS A ) offers an excellent parameter to assess improvements in insulin sensitivity. In fact, monitoring DS A across a number of studies reveals that changes in this parameter can account for the response of almost every single patient with respect to insulin sensitivity, and offers a parameter far superior to that of total adiponectin levels. Again, these improvements in the adiponectin complex ratios are not brought about secondary to improvements of insulin sensitivity, since intervention with an activator of a direct downstream target of adiponectin (with a PPARa agonist) remained without consequences on S A . A more detailed analysis in patient samples for which detailed insulin sensitivity measurements were available revealed that correlations with S A held up uniquely with measurements of hepatic insulin sensitivity and failed to display correlations with muscle insulin sensitivity. This is consistent with pharmacological and genetic data that previously highlighted the liver as the primary target of the physiological full-length ligand.
The fact that S A , and not absolute levels of the HMW, yields significant correlations suggests a competitive relationship between the HMW and LMW forms. This competition could play out at the level of the receptor. The structure of the globular head domain of adiponectin bears a high degree of homology to the TNF superfamily of ligands. Signaling through TNF receptor family members is significantly improved by receptor clustering, and a similar mechanism could hold up for adiponectin (Figure 2, top) . On the other hand, there could be a competitive relationship of the HMW and LMW forms at the level of an upstream activator of the ligand such as a serum reductase and/or a protease that proteolytically cleaves the full-length adiponectin complex (Figure 2, bottom) . Evidence that reduction of the full-length protein and subsequent cleavage may play a role in the hepatic effects of the protein has indeed been reported. While still speculative at this stage, these observations offer models that are experimentally testable.
Conclusions and future perspectives
TZD action affects a large number of different genes. The integrated response to TZD treatment with respect to improvements in insulin sensitivity is unlikely to be explained by induction of a single gene. However, with respect to improvements of insulin sensitivity in the liver, adiponectin represents an excellent candidate, mediating at least some aspects of TZD action in the liver. A more detailed quantitative assessment of adiponectin's contributions towards hepatic insulin sensitivity will have to await a more detailed characterization of TZD effects in mice lacking adiponectin. Minimally, changes in the S A index offer an excellent quantitative assessment of TZD effects. Current efforts are directed towards testing the hypothesis that changes in the S A index after as little as 1-2 weeks of TZD treatment may have predictive power with respect to TZD efficacy 3-4 months into the treatment period, thereby allowing the identification of metabolically nonresponsive patients at a much earlier treatment stage that precedes the onset of the TZD-induced weight gain. could be produced through action of a serum-or cell surface-bound reductase activity for which the HMW is a substrate and the LMW a competitive inhibitor. The reduced HMW form dissociates into a trimer, which serves as a substrate for a cell surface-bound protease. The truncated form of adiponectin then triggers activation of downstream signaling cascades such as AMPK.
